- Home
- OCG vs TVRD Comparison
OCG vs TVRD Comparison
Compare OCG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCG | TVRD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 246.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OCG | TVRD |
|---|---|---|
| Price | $0.23 | $4.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 19.7M | 114.5K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $316,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $3.74 |
| 52 Week High | $19.29 | $43.65 |
Technical Indicators
Market Signals| Indicator | OCG | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 34.35 |
| Support Level | $2.60 | $4.05 |
| Resistance Level | $19.29 | $4.71 |
| Average True Range (ATR) | 2.72 | 0.27 |
| MACD | -0.05 | 0.55 |
| Stochastic Oscillator | 0.09 | 73.20 |
Price Performance
Historical ComparisonAbout OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.